Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-PHC-102
- Development stage
- Unknown
- Lead developer
- Philochem
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
99mTc-PHC-102 is a technetium-99m (^99mTc)-labeled acetazolamide derivative used as a radiopharmaceutical for SPECT/CT imaging[1][3][4]. It targets carbonic anhydrase IX (CAIX), a cell surface enzyme highly expressed in clear cell renal cell carcinoma (ccRCC) and other cancers, but low in normal tissues[1][3]. The agent consists of an acetazolamide-based small molecule connected to a peptide chelator for technetium-99m via a triazole-aspartic acid linker[1]. Upon intravenous administration, it binds specifically to CAIX-positive tumor sites, permitting sensitive detection of both primary and metastatic lesions using nuclear imaging. Its mechanism of action is high-affinity, selective binding and labeling of CAIX-expressing cells, thereby enabling imaging and potentially serving as a companion diagnostic for CAIX-targeted therapeutics[1][3][4].
- Brand names
- 99mTc-PHC-102
- Other names
- 99mTc-PHC-102
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on 99mTc-PHC-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-PHC-102.